PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 29, 2026Journal of Clinical Oncology

Long-term survival update of TRUCE-01: A phase 2 study of preoperative tislelizumab combined with low-dose nab-paclitaxel for muscle-invasive bladder cancer (MIBC).

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZhouliang WuYQYunkai QieCSChong Shen

Discussion

Loading...

Member takes

Overview

Randomized trial investigates survival outcomes in MIBC with tislelizumab and nab-paclitaxel, suggesting favorable benefits.

Key Points

  • This trial aimed to evaluate long-term survival outcomes after preoperative treatment for muscle-invasive bladder cancer.
  • Eligible patients received three cycles of tislelizumab plus nab-paclitaxel every 3 weeks.
  • Follow-up included assessments for clinical complete response, event-free survival, overall survival, disease-specific survival, and metastasis-free survival.
  • The study involved 62 patients with muscle-invasive bladder cancer over a median follow-up of 47.4 months.
  • The 4-year event-free survival rate was 59.7%, and overall survival rate was 67.8%.
  • Patients achieving clinical complete response had significantly better overall survival (HR 0.28, 95% CI 0.09–0.83, p = 0.0212).
  • No new safety signals were identified, confirming the treatment's favorable safety profile.

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/6a192ee7fab5b468c4418257https://doi.org/10.1200/jco.2026.44.16_suppl.4585
View Full Paper
Ask AI
Bookmark
Share